Showing results (51-60 of 93) with videos related to
Sort By:
Pageof 10
Frontiers in Oncology|February 2, 2023
Patient specific real-time PCR in precision medicine - Validation of IG/TR based MRD assessment in lymphoid leukemiaAnke Schilhabel, Monika Szczepanowski, Ellen J van Gastel-Mol, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study GroupGabor Kovacs, Sandra Robrecht, Anna Maria Fink, et al.Haematologica|December 9, 2008
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98BRichard F Schlenk, Konstanze Döhner, Michael Kneba, et al.Blood|February 26, 2013
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trialPeter Dreger, Andrea Schnaiter, Thorsten Zenz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.The Lancet. Haematology|August 21, 2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trialPaula Cramer, Moritz Fürstenau, Sandra Robrecht, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2023
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM StudyChristiane Pott, Vindi Jurinovic, Judith Trotman, et al.Blood|July 3, 2010
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trialPeter Dreger, Hartmut Döhner, Matthias Ritgen, et al.Blood|August 27, 2005
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupWolfgang Hiddemann, Michael Kneba, Martin Dreyling, et al.The Lancet. Oncology|August 18, 2018
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trialPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.Pageof 10